Great Point Partners LLC Aeglea Bio Therapeutics, Inc. Transaction History

Great Point Partners LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.5 - $2.66 $1.25 Million - $6.65 Million	2,500,000 New	2,500,000 $1.26 Million
Q1 2022 May 16, 2022	SELL	$1.87 - $4.77 $1.7 Million - $4.34 Million	-910,251 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$3.5 - $8.42 $35,878 - $86,313	10,251 Added 1.14%	910,251 $4.32 Million
Q2 2021 Aug 16, 2021	BUY	$6.32 - $8.38 $2.51 Million - $3.33 Million	397,100 Added 78.96%	900,000 $6.26 Million
Q1 2021 May 17, 2021	BUY	$6.76 - $8.57 $3.4 Million - $4.31 Million	502,900 New	502,900 $3.98 Million

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Great Point Partners LLC with notifications on news.